Leucemia mieloide acuta recidivanterefrattaria, quizartinib prolunga la sopravvivenza complessiva by media4health - Issuu

Search and overview

Search and overview

Close

Features Fullscreen sharing Embed Digital Sales Statistics Articles Social Posts Teams

Designers Marketers Social Media Managers Publishers Use Cases

Resources Blog Help Center Webinars

Fullscreen sharing Embed Digital Sales Statistics Articles Social Posts Teams

Designers Marketers Social Media Managers Publishers Use Cases

Resources Blog Help Center Webinars

Document details

Leucemia mieloide acuta recidivanterefrattaria, quizartinib prolunga la sopravvivenza complessiva

Published on May 11, 2018

About

Il quizartinib prolunga la sopravvivenza complessiva rispetto alla chemioterapia nei pazienti con LMA recidivante/refrattaria con mutazioni di FLT3-ITD

Advertisement

More from media4health

Advertisement

Read more

Advertisement

Suggestions for you

Advertisement

Create once. Share everywhere.

Issuu Inc.

Company
Issuu Features
Solutions
Industries
Products & Resources

Explore Issuu Content

Terms Privacy DMCA Accessibility Do Not Sell My Info